COO Jennifer Jarrett to exit Arcus Biosciences (RCUS), stay on as advisor

Rhea-AI Filing Summary

Arcus Biosciences, Inc. reported that Chief Operating Officer Jennifer Jarrett has decided to resign from her role effective March 30, 2026. The company states that her resignation is not due to any disagreement over operations, policies, or practices.

Jarrett has entered into a separation agreement under which she will provide periodic advisory services through June 30, 2026, helping support continuity during the transition. In return, Arcus agreed to extend the period during which she may exercise any vested stock options to twelve months after termination, and the agreement includes a standard release of claims. The final separation agreement will be filed with the company’s next quarterly Form 10-Q.

Insights

Biotech corporate governance analyst

COO exit is noteworthy but framed as amicable and structured.

The departure of the Chief Operating Officer at Arcus Biosciences is a meaningful management change, but the company emphasizes that it does not stem from any disagreement over business matters. This language is intended to limit concerns about internal conflict or strategic rifts.

The separation agreement keeps Jennifer Jarrett involved as an advisor through June 30, 2026, which may help preserve institutional knowledge during leadership transition. Extending her vested option exercise window to twelve months is a relatively employee-friendly term, suggesting a cooperative relationship rather than a contentious exit.

The ultimate impact will depend on how Arcus realigns responsibilities and communicates its operational leadership structure in upcoming disclosures. Investors often look to future filings, such as the next Form 10-Q, for additional detail on succession plans and any broader organizational changes tied to a senior executive’s resignation.

false000172452100017245212026-03-172026-03-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________________________________________________

FORM 8-K

________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 17, 2026

________________________________________________________

Arcus Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

________________________________________________________

Delaware

001-38419

47-3898435

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

3928 Point Eden Way

Hayward, California

94545

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 694-6200

(Former Name or Former Address, if Changed Since Last Report)

________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $0.0001 Per Share

RCUS

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 17, 2026, Jennifer Jarrett notified Arcus Biosciences, Inc. (the “Company”) of her decision to resign from her position as Chief Operating Officer, effective as of March 30, 2026. Ms. Jarrett’s resignation is not the result of any disagreement with the Company regarding its operations, policies or practices.

The Company and Ms. Jarrett entered into a separation agreement pursuant to which Ms. Jarrett will make herself available for periodic advisory services for a period through June 30, 2026. In consideration for such services, the Company agreed to extend the post-termination option exercise period during which she may continue to exercise any vested options to twelve (12) months. The separation agreement also contains a standard release of claims. The foregoing description of the separation agreement does not purport to be complete, and is qualified in its entirety by reference to the final separation agreement, a copy of which will be filed with the Company’s next quarterly filing on Form 10-Q.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ARCUS BIOSCIENCES, INC.
Date: March 23, 2026			By:			/s/ Terry Rosen, Ph. D.
						Terry Rosen, Ph.D.
						Chief Executive Officer (Principal Executive Officer)

FAQ

Why did Arcus Biosciences (RCUS) announce the resignation of its COO?

Arcus Biosciences announced that Chief Operating Officer Jennifer Jarrett will resign effective March 30, 2026. The company explicitly states that her decision is not due to any disagreement regarding its operations, policies, or practices, framing the departure as an amicable leadership transition.

When is Arcus Biosciences COO Jennifer Jarrett’s resignation effective?

Chief Operating Officer Jennifer Jarrett will step down from her role effective March 30, 2026. After that date, she will no longer serve as COO but will remain involved with Arcus Biosciences in an advisory capacity under a separation agreement that runs through June 30, 2026.

Will Jennifer Jarrett continue working with Arcus Biosciences (RCUS) after resigning as COO?

Yes. Under a separation agreement, Jennifer Jarrett will provide periodic advisory services for Arcus Biosciences through June 30, 2026. This arrangement is designed to support continuity during the leadership transition while she steps away from day-to-day responsibilities as Chief Operating Officer.

What compensation terms did Arcus Biosciences agree to in Jennifer Jarrett’s separation?

In exchange for advisory services, Arcus Biosciences agreed to extend the post-termination stock option exercise period for Jennifer Jarrett to twelve months. This applies to her vested options and effectively gives her more time to exercise equity awards after her COO role ends.

Does Arcus Biosciences report any disagreement related to the COO’s resignation?

No. The company states that Ms. Jarrett’s resignation is not the result of any disagreement with Arcus Biosciences regarding its operations, policies, or practices. This wording aims to reassure stakeholders that the leadership change is not driven by internal disputes or governance conflicts.

Where can investors find the full details of Jennifer Jarrett’s separation agreement with Arcus Biosciences (RCUS)?

Arcus Biosciences plans to file the final separation agreement with its next quarterly Form 10-Q. Investors seeking complete legal terms, including any additional provisions beyond the summary, will be able to review the full document once that quarterly report is published.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB